Portfolio companies news

06 November 2015

Marinus Pharmaceuticals Announces Public Offering of Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Jefferies LLC and RBC Capital Markets, LLC are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

03 November 2015

NovaDigm Therapeutics’ Chief Executive Officer, Timothy Cooke, Appointed to the National Vaccine Advisory Committee

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that Timothy Cooke, Ph.D., NovaDigm’s Chief Executive Officer, has been appointed to a four-year term on the National Vaccine Advisory Committee (NVAC) by Karen B. DeSalvo, M.D., MPH, MSc, Acting Assistant Secretary for Health at the U.S. Department of Health and Human Services.

02 November 2015

Epic Sciences' Platform Capable of Single Cell CTC Identification Sequencing in Late Stage, Metastatic Cancer

After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug resistance or susceptibility. Tissue biopsies may not detect these subpopulations, but a liquid biopsy of blood using Epic Sciences' no cell left behind® technology may help identify these important tumor cells and characterize how a patient's tumors have evolved over time.

02 November 2015

Clinical Data Demonstrating Significant Improvements in Near and Intermediate Vision with ReVision Optics’ Raindrop Near Vision Inlay Published in Journal of Cataract Refractive Surgery

ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data on the company’s Raindrop® Near Vision Inlay was published in the peer-reviewed Journal of Cataract Refractive Surgery. The Raindrop Inlay is a microscopic hydrogel inlay designed to improve near and intermediate vision, thus reducing the need for reading glasses.

30 October 2015

Transcend Medical and Glaukos Corporation Settle Patent Litigation

Transcend Medical, Inc. ("Transcend") announced today that it has reached agreement with Glaukos Corporation ("Glaukos") to settle the patent litigation pending between them in the U.S. District Court for the District of Delaware. Among other things, the settlement provides that in exchange for a perpetual, worldwide covenant by Glaukos not to sue Transcend's CyPass minimally invasive glaucoma surgery (MIGS) technologies on any of Glaukos' patents, Transcend will provide Glaukos with a one percent (1%), dollar- and time-capped payment on Transcend's commercial CyPass sales. 

29 October 2015

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the third quarter ended September 30, 2015.
 

29 October 2015

Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced today the initiation of the clinical phase of its intravenous (IV) ganaxolone program in Status Epilepticus (SE). Data from preclinical studies yielded positive results testing ganaxolone IV in benzodiazepine-resistant SE, which support progressing ganaxolone IV to human clinical trials. Ganaxolone IV promoted survival and showed better or comparable reversal of seizures than the endogenous neurosteroid, allopregnanolone, in clinically translatable rodent models of SE.  The studies were conducted at two separate laboratories using different measurements. 

26 October 2015

Marinus Announces Key Initial Observations From Study in PCDH19 Female Pediatric Epilepsy

Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced key observations from patients enrolled in its ongoing study evaluating ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, as a treatment for PCDH19 female pediatric epilepsy.  PCDH19 is a serious and rare epileptic syndrome characterized by highly variable early-onset cluster seizures, and cognitive and behavioral disturbances.  Enrollment is continuing in the study with full data expected in 2016. 

22 October 2015

Transcend Medical Submits Final Module of FDA Premarket Approval Application for the CyPass® Glaucoma Micro-Stent

Transcend Medical, Inc., a pioneer of minimally invasive glaucoma surgery (MIGS), today announced the submission to the U.S. Food and Drug Administration (FDA) of the final module of the company’s Premarket Approval (PMA) application for the CyPass® Micro-Stent.

12 October 2015

Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space (SCS™) Drug Administration

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced completion of enrollment in the company’s Phase 2 clinical trial (Dogwood) of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using SCS™ drug administration for the treatment of macular edema associated with non-infectious uveitis. Clearside remains on track to report top-line Phase 2 CLS-TA data by the end of 2015.